Oleocanthal functional food products for breast cancer recurrence control
用于控制乳腺癌复发的油橄榄功能性食品
基本信息
- 批准号:10276305
- 负责人:
- 金额:$ 5.48万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-01 至 2022-05-31
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelBreast Cancer PatientBreast Cancer PreventionConsumptionDataDietDoseEffectivenessExcisionFormulationFutureHumanHuman PathologyImmunocompetentIncidenceMammary glandMolecular TargetMouse Mammary Tumor VirusNatural ProductsNeoadjuvant TherapyNeoplasm MetastasisNude MiceNutraceuticalOlive oil preparationOperative Surgical ProceduresOralOutcomePaclitaxelPatientsPhenolsPowder dose formPreventive treatmentPrimary NeoplasmRecording of previous eventsRecurrenceRegimenSignal PathwaySolidSurvival RateTaste PerceptionTestingTherapeuticTransgenic Micebioactive natural productsbreast cancer progressioncancer recurrencecommercializationdisorder later incidence preventionefficacy testingfunctional foodimprovedmalignant breast neoplasmmouse modelparent grantpatient subsetspreventtriple-negative invasive breast carcinomatumor
项目摘要
SUMMARY
From Parent Grant (R41CA247025)
Triple negative breast cancer (TNBC) represents 20% of the breast cancer (BC) cases in the US. TNBC patients
have a poor recurrence-free, overall survival rate, and limited available treatment options. The Mediterranean
olive oil-rich diet is documented to reduce BC incidence. (-)-Oleocanthal (OC) is a natural phenolic secoiridoid
exclusively occurring in extra-virgin olive oil (EVOO) and it has shown selective anti-BC activities, including
preliminary results showing prevention of recurrence of TNBC in animal models. The HGF/Met signaling
pathway, a validated major OC molecular target, is likely involved in initiating aggressive and recurrent TNBC in
a subset of patients. To improve taste, dissolution and stability, a solid dispersion formulation of OC (OC-X) was
recently developed and characterized. We hypothesize that the EVOO powdered formulation of OC, OC-X,
could be developed as a nutraceutical product to help control locoregional TNBC recurrence. This will be
tested in the following Specific Aims. In the first aim, we will perform dose dependent studies to determine the
optimal effective dose of orally administered OC-X on tumor recurrence in a nude mouse model after primary
tumor surgical resection. This aim will assess the efficacy of formulations in preventive, treatment, and after
completion of paclitaxel neoadjuvant regimen modes. In the second aim, we will perform dose dependent studies
to determine the optimal effective dose of orally administered OC-X on tumor recurrence in the MMTV-PyMT
transgenic mouse model. This immune competent mouse model develops BC mimicking progression seen in
human patients and will be used to assess BC recurrence (after surgical excision of early mammary gland
tumors) and metastasis following treatment with OC-X. Expected outcomes: EVOO enriched in OC has been
safely consumed throughout human history with increasing evidence of effectiveness against many human
pathologies, including BC. Given the lack of other safe therapeutic alternatives, OC is a candidate bioactive
natural product that could be safe for long-term use to prevent BC recurrence. The data generated by this project
will be combined with future studies of OC-X to facilitate commercialization of OC-X as a nutraceutical product
to prevent BC recurrence.
总结
来自父母补助金(R41 CA 247025)
三阴性乳腺癌(TNBC)占美国乳腺癌(BC)病例的20%。TNBC患者
无复发率低,总生存率低,可用的治疗方案有限。地中海
据记录,富含橄榄油的饮食可以减少BC的发病率。(-)-油花醛(OC)是一种天然酚类开环环烯醚萜
它只存在于特级初榨橄榄油(EVOO)中,并显示出选择性的抗BC活性,包括
初步结果显示在动物模型中预防TNBC复发。HGF/Met信号通路
途径是一种经验证的主要OC分子靶点,可能参与启动侵袭性和复发性TNBC,
一部分病人为了改善口感、溶解性和稳定性,制备了OC(OC-X)的固体分散体制剂。
最近开发和鉴定的。我们假设,OC,OC-X,
可以开发为营养产品,以帮助控制局部TNBC复发。这将是
在以下具体目标中进行测试。在第一个目标中,我们将进行剂量依赖性研究,以确定
口服给予OC-X对裸鼠模型中肿瘤复发的最佳有效剂量
肿瘤手术切除该目的将评估制剂在预防、治疗和治疗后的功效。
完成紫杉醇新辅助治疗方案模式。在第二个目标中,我们将进行剂量依赖性研究
确定口服OC-X对MMTV-PyMT中肿瘤复发的最佳有效剂量
转基因小鼠模型。这种免疫活性小鼠模型发展出BC,模拟在
并将用于评估BC复发(在手术切除早期乳腺后
肿瘤)和转移。预期结果:富含OC的EVOO已
在整个人类历史中安全食用,越来越多的证据表明对许多人类有效。
病理学,包括BC。鉴于缺乏其他安全的治疗替代品,OC是一种候选的生物活性物质,
天然产品,可以安全地长期使用,以防止BC复发。这个项目产生的数据
将与OC-X的未来研究相结合,以促进OC-X作为营养产品的商业化
防止BC复发。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Comparative Gene Signature of (-)-Oleocanthal Formulation Treatments in Heterogeneous Triple Negative Breast Tumor Models: Oncological Therapeutic Target Insights.
- DOI:10.3390/nu13051706
- 发表时间:2021-05-18
- 期刊:
- 影响因子:5.9
- 作者:Qusa MH;Abdelwahed KS;Siddique AB;El Sayed KA
- 通讯作者:El Sayed KA
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KHALID A EL SAYED其他文献
KHALID A EL SAYED的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KHALID A EL SAYED', 18)}}的其他基金
Targeting PCSK9 axis for castration-resistant prostate cancer recurrence suppression
靶向 PCSK9 轴抑制去势抵抗性前列腺癌复发
- 批准号:
10555260 - 财政年份:2022
- 资助金额:
$ 5.48万 - 项目类别:
Targeting PCSK9 axis for castration-resistant prostate cancer recurrence suppression
靶向 PCSK9 轴抑制去势抵抗性前列腺癌复发
- 批准号:
10429627 - 财政年份:2022
- 资助金额:
$ 5.48万 - 项目类别:
Design of novel c-Met inhibitors inspired by olive phenolics
受橄榄酚类启发的新型 c-Met 抑制剂的设计
- 批准号:
8434417 - 财政年份:2013
- 资助金额:
$ 5.48万 - 项目类别:
MARINE NATURAL PRODUCTS AS ANTI-ANGIOGENIC AND ANTI-INVASIVE AGENTS
海洋天然产品作为抗血管生成和抗侵袭剂
- 批准号:
7959461 - 财政年份:2009
- 资助金额:
$ 5.48万 - 项目类别:
MARINE NATURAL PRODUCTS AS ANTI-ANGIOGENIC AND ANTI-INVASIVE AGENTS
海洋天然产品作为抗血管生成和抗侵袭剂
- 批准号:
7719997 - 财政年份:2008
- 资助金额:
$ 5.48万 - 项目类别:
MARINE NATURAL PRODUCTS AS ANTI-ANGIOGENIC AND ANTI-INVASIVE AGENTS
海洋天然产品作为抗血管生成和抗侵袭剂
- 批准号:
7609940 - 财政年份:2007
- 资助金额:
$ 5.48万 - 项目类别:
DEVELOPMENT OF MARINE MACROLIDES LATRUNCULINS AS ANGIOGENESIS MODULATORS
作为血管生成调节剂的海洋大环内酯 Latrunculins 的开发
- 批准号:
7381335 - 财政年份:2006
- 资助金额:
$ 5.48万 - 项目类别:
ANTICANCER AND ANTI-INFECTIVE METABILITES FOR SYMBIOTIC MARINE MICROORGANISMS
共生海洋微生物的抗癌和抗感染代谢物
- 批准号:
7381336 - 财政年份:2006
- 资助金额:
$ 5.48万 - 项目类别:
DEVELOPMENT OF THE MARINE MACROLIDES LATRUNCULINS
海洋大环内酯类 LATRUNCULINS 的开发
- 批准号:
6981539 - 财政年份:2003
- 资助金额:
$ 5.48万 - 项目类别:
相似海外基金
Research Project 2 Proteogenomic-guided therapeutic targeting of breast cancer patient-derived xenograft metastases
研究项目 2 蛋白质基因组引导的乳腺癌患者异种移植转移的治疗靶向
- 批准号:
10733315 - 财政年份:2023
- 资助金额:
$ 5.48万 - 项目类别:
SQLE and Sterols Contribute to Racial Disparity in ER+ Breast Cancer Patient Survival
SQLE 和甾醇导致 ER 乳腺癌患者生存率的种族差异
- 批准号:
10571020 - 财政年份:2023
- 资助金额:
$ 5.48万 - 项目类别:
Washington University PDX Development and Trial Center - Evaluation of Abemaciclib in Combination with Olaparib in Ovarian Cancer and Breast Cancer Patient-derived Xenograft Models
华盛顿大学 PDX 开发和试验中心 - Abemaciclib 联合 Olaparib 在卵巢癌和乳腺癌患者异种移植模型中的评估
- 批准号:
10582164 - 财政年份:2022
- 资助金额:
$ 5.48万 - 项目类别:
Identification of Mammaglobin-A breast derived EVs in breast cancer patient plasma using nanoscale flow cytometry
使用纳米级流式细胞术鉴定乳腺癌患者血浆中的乳房珠蛋白-A 乳源性 EV
- 批准号:
411913 - 财政年份:2019
- 资助金额:
$ 5.48万 - 项目类别:
Identifying predictors of racial disparity in treatment and mortality among patients diagnosed with breast cancer in South Carolina and geospatial investigation of breast cancer patient navigation
确定南卡罗来纳州乳腺癌患者治疗和死亡率种族差异的预测因素以及乳腺癌患者导航的地理空间调查
- 批准号:
9978735 - 财政年份:2019
- 资助金额:
$ 5.48万 - 项目类别:
Maximizing metastatic breast cancer patient outcomes using diet and exercise
通过饮食和运动最大限度地提高转移性乳腺癌患者的治疗效果
- 批准号:
388211 - 财政年份:2018
- 资助金额:
$ 5.48万 - 项目类别:
Operating Grants
Identifying predictors of racial disparity in treatment and mortality among patients diagnosed with breast cancer in South Carolina and geospatial investigation of breast cancer patient navigation
确定南卡罗来纳州乳腺癌患者治疗和死亡率种族差异的预测因素以及乳腺癌患者导航的地理空间调查
- 批准号:
9435745 - 财政年份:2017
- 资助金额:
$ 5.48万 - 项目类别:
Identifying predictors of racial disparity in treatment and mortality among patients diagnosed with breast cancer in South Carolina and geospatial investigation of breast cancer patient navigation
确定南卡罗来纳州乳腺癌患者治疗和死亡率种族差异的预测因素以及乳腺癌患者导航的地理空间调查
- 批准号:
9567963 - 财政年份:2017
- 资助金额:
$ 5.48万 - 项目类别:
Development of long term support program for breast cancer patient after reconstruction
为乳腺癌患者重建后制定长期支持计划
- 批准号:
16K20779 - 财政年份:2016
- 资助金额:
$ 5.48万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Development of a Smartphone-integrated Cancer Biomarker Sensor for Breast Cancer Patient Management
开发用于乳腺癌患者管理的智能手机集成癌症生物标志物传感器
- 批准号:
478406-2015 - 财政年份:2015
- 资助金额:
$ 5.48万 - 项目类别:
Experience Awards (previously Industrial Undergraduate Student Research Awards)














{{item.name}}会员




